These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 19509501)

  • 1. Current management of erectile dysfunction after cancer treatment.
    Peltier A; van Velthoven R; Roumeguère T
    Curr Opin Oncol; 2009 Jul; 21(4):303-9. PubMed ID: 19509501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on erectile dysfunction in prostate cancer patients.
    Kendirci M; Bejma J; Hellstrom WJ
    Curr Opin Urol; 2006 May; 16(3):186-95. PubMed ID: 16679857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penile rehabilitation following radical prostatectomy.
    Mulhall JP
    Curr Opin Urol; 2008 Nov; 18(6):613-20. PubMed ID: 18832948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
    Lee IH; Sadetsky N; Carroll PR; Sandler HM
    J Urol; 2008 Mar; 179(3):1072-6; discussion 1076. PubMed ID: 18206926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
    Salonia A; Gallina A; Zanni G; Briganti A; Dehò F; Saccà A; Suardi N; Barbieri L; Guazzoni G; Rigatti P; Montorsi F
    Eur Urol; 2008 Mar; 53(3):564-70. PubMed ID: 17761385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current state of penile rehabilitation after radical prostatectomy.
    Garcia FJ; Brock G
    Curr Opin Urol; 2010 May; 20(3):234-40. PubMed ID: 20224415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erectile dysfunction after radical prostatectomy].
    Becker AJ; Stief CG; Stadler TC
    Aktuelle Urol; 2009 Sep; 40(5):289-93. PubMed ID: 19731191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erectile rehabilitation after radical prostatectomy].
    Droupy S; Giuliano F; Costa P;
    Prog Urol; 2009 Dec; 19 Suppl 4():S193-7. PubMed ID: 20123519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rehabilitation of erectile function following radical prostatectomy.
    McCullough AR
    Asian J Androl; 2008 Jan; 10(1):61-74. PubMed ID: 18087645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and management of erectile dysfunction after various treatments for prostate cancer.
    Soh J; Kaiho Y; Kikuchi E; Oya M; Yoshioka K; Nakagami Y; Hatano T; Ozu C; Horiguchi Y; Namiki K; Tachibana M; Hisasue S; Tanaka N; Asakawa I
    Int J Urol; 2010 Aug; 17(8):689-97. PubMed ID: 20590940
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP).
    Gontero P; Kirby R
    Prostate Cancer Prostatic Dis; 2004; 7(3):223-6. PubMed ID: 15249931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sexual dysfunction after curietherapy and external radiotherapy of the prostate for localized prostate cancer].
    Huyghe E; Bachaud JM; Achard JL; Bossi A; Droupy S;
    Prog Urol; 2009 Dec; 19 Suppl 4():S173-6. PubMed ID: 20123514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress.
    Matthew AG; Goldman A; Trachtenberg J; Robinson J; Horsburgh S; Currie K; Ritvo P
    J Urol; 2005 Dec; 174(6):2105-10. PubMed ID: 16280737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile function outcome reporting after clinically localized prostate cancer treatment.
    Burnett AL; Aus G; Canby-Hagino ED; Cookson MS; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus S; Liebert M; Moul JW; Tangen C; Thrasher JB; Thompson I;
    J Urol; 2007 Aug; 178(2):597-601. PubMed ID: 17570435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy.
    Zippe CD; Pahlajani G
    Urol Clin North Am; 2007 Nov; 34(4):601-18, viii. PubMed ID: 17983900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile aid use by men treated for localized prostate cancer.
    Bergman J; Gore JL; Penson DF; Kwan L; Litwin MS
    J Urol; 2009 Aug; 182(2):649-54. PubMed ID: 19535108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.